Last updated: February 22, 2026
What is the drug associated with NDC 51407-0390?
NDC 51407-0390 corresponds to Eliquis (apixaban), an oral anticoagulant used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and for postoperative thromboprophylaxis.
What is the current market landscape for Eliquis?
Eliquis has established itself as a leading anticoagulant in the U.S., competing primarily with Xarelto (rivaroxaban) and Pradaxa (dabigatran).
Market share and sales data
| Year |
Market share (by sales) |
Estimated U.S. sales (USD millions) |
| 2020 |
31% |
$4.2 billion |
| 2021 |
35% |
$4.8 billion |
| 2022 |
36% |
$5.2 billion |
(IQVIA, 2022)
Key competitors
- Xarelto (rivaroxaban): Market share 28%
- Pradaxa (dabigatran): Market share 15%
- Other: 21%
Market growth trends
Between 2020-2022, Eliquis's market share increased, driven by expanding indications and physician preference for its safety profile, notably lower bleeding risk compared to competitors.
What are the medical and regulatory factors influencing market potential?
- Expanded indications: FDA approvals for additional uses such as pediatric DVT and PE treatment.
- Guideline recommendations: Class I recommendation for non-valvular atrial fibrillation.
- Patent landscape: Patents expire in the next 3-5 years, creating potential for biosimilar entries.
- Pricing and reimbursement: Currently premium-priced (per-course costs range from $300-$500), with insurers favoring Eliquis due to efficacy and safety profiles.
What are the price projections for Eliquis for the next five years?
Current pricing trends
Average wholesale price (AWP): ~$4.00 per 2.5 mg tablet; ~$4.50 per 5 mg tablet (GoodRx, 2023). Net price after rebates is estimated at 60-70% of AWP.
Assumptions for projections
- Price reductions due to biosimilar competition expected to commence within 3-5 years.
- Volume growth driven by new indications and increasing prevalence of atrial fibrillation.
- Impact of patent expiries on pricing elasticity.
Price projection table (per 30-day supply)
| Year |
Estimated average price (USD) |
Notes |
| 2023 |
$470 |
Current market price |
| 2024 |
$440 |
Slight decrease due to rebates |
| 2025 |
$410 |
Entry of biosimilar competitors begins |
| 2026 |
$380 |
Increased biosimilar market penetration |
| 2027 |
$350 |
Greater biosimilar impact expected |
Prices are based on historic trends and conservative estimates of biosimilar market entry, assuming a 5-15% annual price decrease post-patent expiry.
How does patent protection influence price and market entries?
- Current patent protections last until late 2025.
- Patent cliffs typically result in 20-30% price drops for originator drugs.
- Biosimilar entrants are expected to price at a 30-50% discount relative to originator, influencing market share shifts.
What are the implications for R&D and investment?
- Competition from biosimilars will erode Eliquis’s market share and price premium after patent expiry.
- Opportunities exist within indications expansion, especially in pediatric and thromboprophylaxis areas.
- Ongoing development of antidotes and combination therapies could sustain market life cycles.
- The competitive landscape favors innovation in delivery methods and cost reduction.
Key Takeaways
- Eliquis commands a significant market share with sustained sales growth driven primarily by its safety profile and expanding indications.
- Price projections decline gradually, influenced by biosimilar entries and patent expiration.
- Biosimilars could reduce prices by 30-50% within five years.
- The market remains lucrative, but competitive pressures necessitate innovation and strategic positioning.
FAQs
Q1: When do biosimilar versions of Eliquis likely enter the market?
A1: Based on patent expiration timelines, biosimilars are expected around late 2025 to early 2026.
Q2: How much can prices decrease upon biosimilar entry?
A2: Prices could fall by 30-50% relative to the originator, depending on market dynamics and reimbursement policies.
Q3: What are the main drivers of Eliquis’s market growth?
A3: Increased prevalence of atrial fibrillation, expanded FDA indications, and physician preference for safety.
Q4: What strategies can manufacturers adopt to maintain market share?
A4: Innovations in delivery, targeted indications, and competitive pricing in emerging markets.
Q5: How does insurance coverage affect Eliquis's pricing?
A5: Rebate programs and formulary placements influence net prices; premium pricing can be mitigated by payer negotiations.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- GoodRx. (2023). Drug Pricing Data.
- U.S. Food and Drug Administration. (2022). Eliquis Post-Marketing Approvals.
- EvaluatePharma. (2022). World Market Forecasts.
- Medicare & Medicaid Pricing Policies. (2023). Reimbursement and Pricing Guidelines.
